Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Debt / NOTE 1.750% 2/1
-
Number of holders
-
25
-
Total principal
-
262M
-
Principal change
-
+4.09M
-
Total reported value, excl. options
-
$330M
-
Value change
-
+$1.16M
-
Number of buys
-
11
-
Number of sells
-
-11
-
Price
-
$1.17
Significant Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q2 2021
25 filings reported holding 761330AB5 - REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q2 2021.
REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 has 25 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $262M of principal
.
Largest 10 bondholders include CITADEL ADVISORS LLC ($104M of principal), FRANKLIN RESOURCES INC ($48M of principal), LAZARD ASSET MANAGEMENT LLC ($20M of principal), ZAZOVE ASSOCIATES LLC ($15.9M of principal), CAPSTONE INVESTMENT ADVISORS, LLC ($12.5M of principal), PUTNAM INVESTMENTS LLC ($8.92M of principal), Nuveen Asset Management, LLC ($8.68M of principal), MORGAN STANLEY ($7.15M of principal), ROYAL BANK OF CANADA ($4.93M of principal), and DeepCurrents Investment Group LLC ($4.92M of principal).
This table shows the top 25 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.